Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/fon.15.232 http://scihub22266oqcxt.onion/10.2217/fon.15.232 C4976858!4976858!26403973     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Future+Oncol 2015 ; 11 (21): 2865-71 Nephropedia Template TP {{tp|p=26403973|t=2015. Denosumab: a new agent in the management of hypercalcemia of malignancy |pdf=|usr=}}{{26403973}} gab.com Text Denosumab: a new agent in the management of hypercalcemia of malignancy JO: Future Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26403973 #FOAvip Hypercalcemia of malignancy is an oncologic emergency due to tumoral factors that stimulate osteoclast-mediated bone resorption. It requires a combination of recommended treatments (i.e., hydration, bisphosphonate and calcitonin), which may be deleterious in patients with compromised cardiac or renal function or may not control serum calcium levels long term. Recurrent or refractory hypercalcemia may preclude the use of chemotherapeutic agents needed to effectively treat the underlying cancer, which is the cause of hypercalcemia. Denosumab, a fully human monoclonal antibody against RANKL, inhibits the maturation, function and survival of osteoclasts. An open-label, single-arm study of denosumab in patients with hypercalcemia of malignancy despite recent bisphosphonate treatment revealed positive results. Thus, the US FDA recently approved denosumab for the indication of hypercalcemia of malignancy, increasing the options available for patients with this debilitating and life-threatening condition. Twit Text FOAVip Denosumab: a new agent in the management of hypercalcemia of malignancy ????Future Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26403973 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26403973 #FOAvip English Wikipedia <ref>{{Cite pmid|26403973}}</ref> Denosumab: a new agent in the management of hypercalcemia of malignancy #MMPMID26403973 Thosani S; Hu MI Future Oncol 2015[Nov]; 11 (21): 2865-71 PMID26403973show ga Hypercalcemia of malignancy is an oncologic emergency due to tumoral factors that stimulate osteoclast-mediated bone resorption. It requires a combination of recommended treatments (i.e., hydration, bisphosphonate and calcitonin), which may be deleterious in patients with compromised cardiac or renal function or may not control serum calcium levels long term. Recurrent or refractory hypercalcemia may preclude the use of chemotherapeutic agents needed to effectively treat the underlying cancer, which is the cause of hypercalcemia. Denosumab, a fully human monoclonal antibody against RANKL, inhibits the maturation, function and survival of osteoclasts. An open-label, single-arm study of denosumab in patients with hypercalcemia of malignancy despite recent bisphosphonate treatment revealed positive results. Thus, the US FDA recently approved denosumab for the indication of hypercalcemia of malignancy, increasing the options available for patients with this debilitating and life-threatening condition. äDenosumab: a new agent in the management of hypercalcemia of malignanc(epmc).pdf DeepDyve Pubget Overpricing